AERI - Aerie Pharmaceuticals, Inc.
| Previous Close | 22.91 |
| Open | 23.36 |
| Bid | 22.57 x 1100 |
| Ask | 22.65 x 800 |
| Day's Range | 22.23 - 23.53 |
| 52 Week Range | 18.02 - 63.20 |
| Volume | 498,984 |
| Avg. Volume | 1,072,989 |
| Market Cap | 1.103B |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.17 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.11 |
- Business Wire
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension. The CHMP positive opinion is a scientific recommendation for marketing authorisation referred to the European Commission for a final decision on the Company’s MAA.
- Benzinga
The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...
- Simply Wall St.
Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money?
As the US$994m market cap Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released another year of negative earnings...
- Business Wire
Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA). If approved, the PAS will permit production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the United States in Aerie’s new manufacturing plant in Athlone, Ireland.
- GuruFocus.com
Weekly CEO Buys Highlight
Insiders invest in Cigna, Bausch Health, At Home Group, Aerie Pharmaceuticals and REV Group Continue reading...
- Business Wire
Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the initial purchasers of the previously announced offering of Aerie’s 1.50% Convertible Senior Notes due 2024 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to fully exercise their option to purchase an additional $41.25 million aggregate principal amount of the notes. The settlement of the sale of additional notes pursuant to the option is expected to occur on September 12, 2019, subject to customary closing conditions.
- GuruFocus.com
Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Bought $499,012 of Shares
CEO of Aerie Pharmaceuticals Inc (30-Year Financial, Insider Trades) Vicente Jr Anido (insider trades) bought 26,250 shares of AERI on 09/09/2019 at an average price of $19.01 a share. Continue reading...
- TheStreet.com
These 2 Biotech Stocks Are Seeing Insider Buying Activity
Helping to buoy investor sentiment was the announcement that China and the United States will meet face to face in October in the next round of trade talks. The unemployment rate among several demographics is at the lowest levels ever measured. The consumer part of the economy remains in very solid shape with wage growth at or near its highest levels in over a decade with still more job openings than people to fill them.
- American City Business Journals
Durham pharma embarks on $275M financial trade
A Durham-based pharmaceutical maker is trading out its credit facilities through a $275 convertible note offering meant to revamp the company's finances as it inches towards profitability.
- Zacks
Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Benzinga
The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 4) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Bioanalytical ...
- Business Wire
Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has priced $275 million aggregate principal amount of its 1.50% convertible senior notes due 2024 (the “notes”). The offering was increased to $275 million aggregate principal amount of notes from the previously announced offering size of $250 million aggregate principal amount of notes. Aerie has also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $41.25 million aggregate principal amount of the notes.
- Business Wire
Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it proposes to offer $250 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”), subject to market conditions and other factors. The notes are to be offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Aerie also intends to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of the notes.
- Business Wire
Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs, reporting to Welyn Bui, PharmD, Aerie’s Vice President of Medical Affairs. Dr. Vargas will oversee the organizational planning and operational needs of medical affairs at Aerie.
- Business Wire
Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) Implant in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
- GuruFocus.com
Zuckerberg Sells Shares of Facebook
Largest insider trades of the past week Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT
Q2 2019 Aerie Pharmaceuticals Inc Earnings Call
- Investor's Business Daily
This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
Investors punished biotech companies Sarepta Therapeutics and Arena Pharmaceuticals on growing losses in the second quarter, and lauded Aerie Pharmaceuticals for its guidance cut.
- Zacks
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
- Simply Wall St.
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI): Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company...
Motley FoolAerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript
AERI earnings call for the period ending June 30, 2019.
- Zacks
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of 8.05% and 8.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
Conference Call and Webcast Today, August 7th, at 5:00 p.m. ET
- Zacks
Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
Analysts Recommend Buying These 2 Falling Knives
Aerie Pharmaceuticals Inc. IntriCon Corp do not have debt Continue reading...
